SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies ...
(RTTNews) - Immuneering Corp. (IMRX), Tuesday announced positive data update from three arms of its ongoing Phase 2a trial of lead program IMM-1-104 for the treatment of patients with Pancreatic ...
With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA Orphan Drug Designation granted to elraglusib for the same indication reflect elraglusib’s ...
Immuneering Corporation (NASDAQ:IMRX) on Tuesday announced plans to add three new combination arms for its Phase 2a program ...
The proportion of patients who have been diagnosed with cancer at an early stage in England is at its highest ever level ...
A new mouse study by researchers at the University of California (UC), San Diego, School of Medicine reveals that an enzyme ...
Cell therapies have suffered from hyped-up expectations, clinical setbacks and high costs. But maybe, just maybe, Arovella is ...
Richard Hays, a renowned New Testament scholar and former dean of Duke Divinity School known for his influential books on ...
Tumor Treating Fields therapy demonstrates increased overall survival in patients with unresectable pancreatic cancer. The ...
Richard B. Hays, the former dean and George Washington Ivey Professor Emeritus of New Testament at Duke Divinity School, has ...
The Brighterside of News on MSN2d
Groundbreaking mRNA vaccine revolutionizes pancreatic cancer treatmentLong before mRNA vaccines captured global attention during the COVID-19 pandemic, researchers were already exploring their ...
Huch’s pancreatic organoids are now a promising avenue for disease modeling and generating precision medicines to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback